Discussing PsA: Bimekizumab in PsA: Clinical efficacy and updated safety profile
From The IMID Forum by The Immune-Mediated Inflammatory Disease Forum
April 14, 2026 · 17 min
About this episode
The episode discusses the clinical efficacy and updated safety profile of bimekizumab in patients with active PsA.
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘safety and clinical efficacy of bimekizumab in patients with active PsA who were bDMARD-naïve or TNFi-IR, and the second provided a comprehensive and updated overview of bimekizumab’s safety profile to support clinical decision-making.
People in this episode
Host: Professor Laura Coates
Guest: Phillip Mease
Topics covered
- PsA
- bimekizumab
- clinical efficacy
- safety profile
- bDMARD-naïve
- TNFi-IR
Keywords
- PsA
- bimekizumab
- clinical efficacy
- safety profile
- bDMARD-naïve
- TNFi-IR
Mentioned in this episode
Products: bimekizumab
Books & works: PsA
More episodes of The IMID Forum
- EULAR 2026 Review Podcast · June 12, 2026 · 40 min
- EULAR 2026 Day 4 Highlights Podcast · June 6, 2026 · 5 min
- EULAR 2026 Day 3 Highlights Podcast · June 5, 2026 · 3 min
- EULAR 2026 Day 2 Highlights Podcast · June 4, 2026 · 6 min
- EULAR 2025 Day 1 Highlights Podcast · June 3, 2026 · 6 min
- Discussing RA: Comparative outcomes with upadacitinib in RA · May 28, 2026 · 9 min
Explore listener stats, chart rankings, contacts and more on the The IMID Forum podcast page.